Mullaney, Keating & Wright’s AbbVie ABBV Stock Holding History

Mullaney, Keating & Wright’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$486K	Hold	1,930	–	–	0.23%	44
2026 Q1	$420K	Hold	1,930	–	–	0.23%	47
2025 Q4	$441K	Hold	1,930	–	–	0.23%	43
2025 Q3	$447K	Hold	1,930	–	–	0.25%	41
2025 Q2	$358K	Hold	1,930	–	–	0.23%	42
2025 Q1	$404K	Sell	1,930 -20	-1%	-$3.89K	0.27%	40
2024 Q4	$347K	Sell	1,950 -30	-2%	-$5.52K	0.23%	43
2024 Q3	$391K	Hold	1,980	–	–	0.27%	42
2024 Q2	$340K	Buy	+1,980	New	+$328K	0.26%	42

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Mullaney, Keating & Wright's ABBV Position: Q2 2026 in Review

Mullaney, Keating & Wright held its AbbVie (ABBV) position steady in Q2 2026 at 1,930 shares worth $486K. The position accounts for 0.23% of the portfolio, ranked #44.

Mullaney, Keating & Wright first reported a position in ABBV in Q2 2024 and has held it in 9 quarters since. 4,209 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Mullaney, Keating & Wright held 1,930 shares of AbbVie worth $486K as of Q2 2026.
Mullaney, Keating & Wright left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.23% of Mullaney, Keating & Wright's portfolio in Q2 2026, its #44 holding.
Mullaney, Keating & Wright first reported a position in AbbVie in Q2 2024 and has held it in 9 quarters since.
4,209 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Mullaney, Keating & Wright's 13F filing for Q2 2026, filed 14 Jul 2026.